

23 Oct 2023 | News

# Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's podcast edition of Five Must-Know Things: Daiichi's huge ADC deal with Merck; mixed data for Rybrevant at ESMO; Pfizer girds for cost cuts; myeloma helps J&J's Q3; and five key points for cell and gene Meeting on the Mesa.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 20 October 2023, including: [Daiichi Sankyo Co., Ltd.](#)'s huge ADC deal with [Merck & Co., Inc.](#); mixed data for Rybrevant at ESMO; [Pfizer Inc.](#) girds for cost cuts; myeloma helps [Johnson & Johnson](#)'s Q3; and five key points from the cell and gene Meeting on the Mesa.

This and all our other podcasts are available on the Pharma Intelligence channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#), [TuneIn](#) and [Spotify Podcasts](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[Daiichi In Massive \\$22bn Global Deal With Merck & Co For Three ADCs](#)" - Scrip, 20 Oct, 2023.)

(Also see "[ESMO 23: MARIPOSA Data Blunt J&J's Rybrevant Threat To Tagrisso](#)" - Scrip, 18 Oct, 2023.)

(Also see "['It's A Very Different Story,' Pfizer CEO Bourla Says Of Cuts To Match COVID Revenue](#)" - Scrip, 16 Oct, 2023.)

# SCRIP

CITELINE COMMERCIAL

(Also see "[\*J&J's Multiple Myeloma Launches Pick Up Momentum\*](#)" - Scrip, 17 Oct, 2023.)

(Also see "[\*Five Key Points From Cell & Gene Meeting On The Mesa\*](#)" - Scrip, 13 Oct, 2023.)

[Click here to explore this interactive content online](#) ✨